GSK halts Excedrin production due to manufacturing inconsistencies
Posted: 22 January 2020 | Victoria Rees (European Pharmaceutical Review) | No comments yet
GlaxoSmithKline has announced that it will not be manufacturing or distributing some of its Excedrin products after inconsistencies in ingredient transfer and weight.
GlaxoSmithKline (GSK) has temporarily stopped manufacturing some of its over the counter (OTC) Excedrin products in the US.
Speaking to European Pharmaceutical Review, a GSK spokesperson explained that through routine quality control and assurance measures, it discovered inconsistencies in the transferring and weighing of ingredients for two products. The medications in question are Excedrin Extra Strength Caplets and Geltabs (acetaminophen/aspirin/caffeine) and Excedrin Migraine Caplets and Geltabs (acetaminophen/aspirin/caffeine). The drugs are for the treatment of pain from headaches and migraines.
Emphasising that safety and product quality are of utmost priority at GSK, the spokesperson added: “Based on the available data, GSK believes that the product does not pose a safety risk to consumers. However, as a precautionary measure, GSK Consumer Healthcare voluntarily implemented a temporary discontinuation of production and distribution.”
According to the company, this is a short-term issue and production is expected to continue in the near future. At present, other Excedrin products are available, however dosages may vary. As such, patients should consult their pharmacist for the most suitable alternative product.
Related topics
Distribution & Logistics, Drug Manufacturing, Drug Safety, Drug Supply Chain, Ingredients, Manufacturing, Production, QA/QC
